Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models
Intraperitoneal (IP) chemotherapy for ovarian cancer treatment prolongs overall survival by 16 months compared to intravenous chemotherapy but is not widely practiced due to catheter-related complications and complexity of administration. An implantable, nonresorbable IP microdevice was used to rele...
| Main Authors: | , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Elsevier
2017
|
| Online Access: | http://hdl.handle.net/1721.1/106467 https://orcid.org/0000-0001-8586-6900 https://orcid.org/0000-0003-2379-6139 |
| _version_ | 1826193502803853312 |
|---|---|
| author | Na, Young Jeong Fulci, Giulia del Carmen, Marcela G. Birrer, Michael J. Ye, Hongye Tanenbaum, Laura Melanie Mantzavinou, Aikaterini Cima, Michael J. |
| author2 | Harvard University--MIT Division of Health Sciences and Technology |
| author_facet | Harvard University--MIT Division of Health Sciences and Technology Na, Young Jeong Fulci, Giulia del Carmen, Marcela G. Birrer, Michael J. Ye, Hongye Tanenbaum, Laura Melanie Mantzavinou, Aikaterini Cima, Michael J. |
| author_sort | Na, Young Jeong |
| collection | MIT |
| description | Intraperitoneal (IP) chemotherapy for ovarian cancer treatment prolongs overall survival by 16 months compared to intravenous chemotherapy but is not widely practiced due to catheter-related complications and complexity of administration. An implantable, nonresorbable IP microdevice was used to release chemotherapeutic agent at a constant rate of approximately 1.3 μg/h in vitro and 1.0 μg/h in vivo. Studies conducted in two orthotopic murine models bearing human xenografts (SKOV3 and UCI101) demonstrate that continuous dosing reduces tumor burden to the same extent as weekly IP bolus drug injections. Treatment-induced toxicity was quantified via body weight loss and complete blood count. The microdevice resulted in significantly less toxicity than IP bolus injections, despite administration of higher cumulative doses (total area under the concentration-time curve of 3049 ng day/mL with the microdevice vs. 2118 ng-day/mL with IP bolus injections). This preclinical study supports the concept that reduced toxicity with similar efficacy outcomes can be achieved by continuous dosing in ovarian cancer patients currently treated with IP therapy. |
| first_indexed | 2024-09-23T09:40:11Z |
| format | Article |
| id | mit-1721.1/106467 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T09:40:11Z |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | mit-1721.1/1064672022-09-30T16:04:59Z Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models Na, Young Jeong Fulci, Giulia del Carmen, Marcela G. Birrer, Michael J. Ye, Hongye Tanenbaum, Laura Melanie Mantzavinou, Aikaterini Cima, Michael J. Harvard University--MIT Division of Health Sciences and Technology Massachusetts Institute of Technology. Department of Materials Science and Engineering Koch Institute for Integrative Cancer Research at MIT Ye, Hongye Tanenbaum, Laura Melanie Mantzavinou, Aikaterini Cima, Michael J Intraperitoneal (IP) chemotherapy for ovarian cancer treatment prolongs overall survival by 16 months compared to intravenous chemotherapy but is not widely practiced due to catheter-related complications and complexity of administration. An implantable, nonresorbable IP microdevice was used to release chemotherapeutic agent at a constant rate of approximately 1.3 μg/h in vitro and 1.0 μg/h in vivo. Studies conducted in two orthotopic murine models bearing human xenografts (SKOV3 and UCI101) demonstrate that continuous dosing reduces tumor burden to the same extent as weekly IP bolus drug injections. Treatment-induced toxicity was quantified via body weight loss and complete blood count. The microdevice resulted in significantly less toxicity than IP bolus injections, despite administration of higher cumulative doses (total area under the concentration-time curve of 3049 ng day/mL with the microdevice vs. 2118 ng-day/mL with IP bolus injections). This preclinical study supports the concept that reduced toxicity with similar efficacy outcomes can be achieved by continuous dosing in ovarian cancer patients currently treated with IP therapy. 2017-01-12T19:59:23Z 2017-01-12T19:59:23Z 2015-11 2015-10 Article http://purl.org/eprint/type/JournalArticle 0168-3659 http://hdl.handle.net/1721.1/106467 Ye, Hongye et al. “Sustained, Low-Dose Intraperitoneal Cisplatin Improves Treatment Outcome in Ovarian Cancer Mouse Models.” Journal of Controlled Release 220 (2015): 358–367. https://orcid.org/0000-0001-8586-6900 https://orcid.org/0000-0003-2379-6139 en_US http://dx.doi.org/10.1016/j.jconrel.2015.11.001 Journal of Controlled Release Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Elsevier Prof. Cima via Angie Locknar |
| spellingShingle | Na, Young Jeong Fulci, Giulia del Carmen, Marcela G. Birrer, Michael J. Ye, Hongye Tanenbaum, Laura Melanie Mantzavinou, Aikaterini Cima, Michael J. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models |
| title | Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models |
| title_full | Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models |
| title_fullStr | Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models |
| title_full_unstemmed | Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models |
| title_short | Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models |
| title_sort | sustained low dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models |
| url | http://hdl.handle.net/1721.1/106467 https://orcid.org/0000-0001-8586-6900 https://orcid.org/0000-0003-2379-6139 |
| work_keys_str_mv | AT nayoungjeong sustainedlowdoseintraperitonealcisplatinimprovestreatmentoutcomeinovariancancermousemodels AT fulcigiulia sustainedlowdoseintraperitonealcisplatinimprovestreatmentoutcomeinovariancancermousemodels AT delcarmenmarcelag sustainedlowdoseintraperitonealcisplatinimprovestreatmentoutcomeinovariancancermousemodels AT birrermichaelj sustainedlowdoseintraperitonealcisplatinimprovestreatmentoutcomeinovariancancermousemodels AT yehongye sustainedlowdoseintraperitonealcisplatinimprovestreatmentoutcomeinovariancancermousemodels AT tanenbaumlauramelanie sustainedlowdoseintraperitonealcisplatinimprovestreatmentoutcomeinovariancancermousemodels AT mantzavinouaikaterini sustainedlowdoseintraperitonealcisplatinimprovestreatmentoutcomeinovariancancermousemodels AT cimamichaelj sustainedlowdoseintraperitonealcisplatinimprovestreatmentoutcomeinovariancancermousemodels |